Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are present
- PMID: 2450260
- DOI: 10.1097/00005344-198801000-00012
Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are present
Abstract
The effect of canrenone, an antialdosterone and partial ouabain-agonist drug, was studied in rats that developed volume expansion and hypertension after renal mass reduction and excess Na+ intake (RRM-salt). The RRM-salt was characterized by: (1) increased endogenous "digitalis-like" compounds in plasma [cross reactivity with digoxin-antibodies (57.5 +/- 5.0 vs. 42.1 +/- 3.8 pg/ml, p less than 0.02); inhibition of kidney Na+, K+-ATPase activity (135 +/- 5 vs. 154 +/- 5 mumol/mg/h, p less than 0.01); and inhibition of Na+ extrusion from normal erythrocytes (5.96 +/- 0.40 vs. 7.68 +/- 0.34 mmol/L cells/h, p less than 0.01)]; (2) reduced Na+, K+-pump activity (7.34 +/- 0.29 vs. 10.88 +/- 0.41 mmol/L cells/h, p less than 0.001) and increased Na+ content (4.66 +/- .08 vs. 4.16 +/- 0.11 mmol/L cells, p less than 0.01) in erythrocytes; and (3) low plasma renin activity (2.1 +/- 0.9 vs. 12.6 +/- 1.6 ng/ml/h). Ninety minutes after the administration to RRM-salt of a single oral dose of 60 mg/kg of canrenone, the systolic blood pressure decreased by 36 +/- 4 mm Hg (mean +/- SEM). Chronic canrenone administration (60 mg/kg/day) resulted in a marked antihypertensive effect associated to a correction of volume expansion, a decrease in endogenous "digitalis-like" compounds, and a partial recovery of Na+, K+-pump activity and Na+ content in erythrocytes. Our results suggest that the antihypertensive effect in RRM-salt rats results, at least in part, from antagonism with endogenous "digitalis-like" compounds.
Similar articles
-
Hypotensive action of canrenone in a model of hypertension where ouabain-like factors are present.J Hypertens Suppl. 1985 Dec;3(3):S73-5. J Hypertens Suppl. 1985. PMID: 2856827
-
[Canrenone: an effective antihypertensive in an experimental model of hypertension in which the active transport of sodium is diminished].Arch Mal Coeur Vaiss. 1986 Jun;79(6):875-8. Arch Mal Coeur Vaiss. 1986. PMID: 3099704 French.
-
Erythrocyte Na+, K+ pump inhibition after saline infusion in essentially hypertensive subjects: effects of canrenone administration.Int J Cardiol. 1989;25 Suppl 1:S47-52. doi: 10.1016/0167-5273(89)90092-2. Int J Cardiol. 1989. PMID: 2620996
-
[The role of an endogenous digoxin-like factor in regulating blood circulation and in the origin of arrhythmia in myocardial ischemia].Ter Arkh. 1989;61(7):84-9. Ter Arkh. 1989. PMID: 2555931 Review. Russian.
-
Endogenous cardiac glycosidelike compounds.Hypertension. 1987 Nov;10(5 Pt 2):I87-92. doi: 10.1161/01.hyp.10.5_pt_2.i87. Hypertension. 1987. PMID: 2824372 Review.
Cited by
-
Endogenous Bufadienolides, Fibrosis and Preeclampsia.Cardiol Res Pract. 2019 Dec 12;2019:5019287. doi: 10.1155/2019/5019287. eCollection 2019. Cardiol Res Pract. 2019. PMID: 31915545 Free PMC article. Review.
-
Canrenone Restores Vasorelaxation Impaired by Marinobufagenin in Human Preeclampsia.Int J Mol Sci. 2022 Mar 19;23(6):3336. doi: 10.3390/ijms23063336. Int J Mol Sci. 2022. PMID: 35328757 Free PMC article.
-
Endogenous digitalis: pathophysiologic roles and therapeutic applications.Nat Clin Pract Nephrol. 2008 Jul;4(7):378-92. doi: 10.1038/ncpneph0848. Epub 2008 Jun 10. Nat Clin Pract Nephrol. 2008. PMID: 18542120 Free PMC article. Review.
-
Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.Pharmacol Rev. 2009 Mar;61(1):9-38. doi: 10.1124/pr.108.000711. Pharmacol Rev. 2009. PMID: 19325075 Free PMC article. Review.
-
Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.J Hypertens. 2015 Aug;33(8):1602-10. doi: 10.1097/HJH.0000000000000591. J Hypertens. 2015. PMID: 26136067 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical